DK1459765T3 - 6-fluorbicyclo 3.1.0 hexan-derivater - Google Patents

6-fluorbicyclo 3.1.0 hexan-derivater

Info

Publication number
DK1459765T3
DK1459765T3 DK02793421T DK02793421T DK1459765T3 DK 1459765 T3 DK1459765 T3 DK 1459765T3 DK 02793421 T DK02793421 T DK 02793421T DK 02793421 T DK02793421 T DK 02793421T DK 1459765 T3 DK1459765 T3 DK 1459765T3
Authority
DK
Denmark
Prior art keywords
group
alkoxy
represent
fluorobicyclo
different
Prior art date
Application number
DK02793421T
Other languages
English (en)
Inventor
Atsuro Nakazato
Shigeyuki Chaki
Kazunari Sakagami
Ryoko Dean
Hiroshi Ohta
Shiho Hirota
Akito Yasuhara
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1459765T3 publication Critical patent/DK1459765T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Lubricants (AREA)
  • Glass Compositions (AREA)
DK02793421T 2001-12-27 2002-12-26 6-fluorbicyclo 3.1.0 hexan-derivater DK1459765T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001395797 2001-12-27
PCT/JP2002/013693 WO2003061698A1 (fr) 2001-12-27 2002-12-26 Derives de 6-fluorobicyclo[3.1.0]hexane

Publications (1)

Publication Number Publication Date
DK1459765T3 true DK1459765T3 (da) 2008-10-06

Family

ID=27602080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02793421T DK1459765T3 (da) 2001-12-27 2002-12-26 6-fluorbicyclo 3.1.0 hexan-derivater

Country Status (24)

Country Link
US (1) US7157594B2 (da)
EP (1) EP1459765B1 (da)
JP (1) JP4230919B2 (da)
KR (2) KR20090031962A (da)
CN (1) CN1281274C (da)
AT (1) ATE405289T1 (da)
AU (1) AU2002359923B2 (da)
BR (1) BR0215462A (da)
CA (1) CA2471642C (da)
CY (1) CY1108380T1 (da)
DE (1) DE60228491D1 (da)
DK (1) DK1459765T3 (da)
ES (1) ES2311642T3 (da)
HK (1) HK1073258A1 (da)
HU (1) HU228436B1 (da)
MX (1) MXPA04006322A (da)
NO (1) NO328844B1 (da)
NZ (1) NZ533699A (da)
PL (1) PL208123B1 (da)
PT (1) PT1459765E (da)
RU (1) RU2315622C2 (da)
SI (1) SI1459765T1 (da)
WO (1) WO2003061698A1 (da)
ZA (2) ZA200404795B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG165981A1 (en) * 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
EP1517915B1 (en) 2002-06-11 2009-01-21 Eli Lilly And Company Prodrugs of excitatory amino acids
US7109383B2 (en) * 2002-09-27 2006-09-19 Central Glass Company, Limited Fluorine-containing allyl ether compounds, their copolymers, and resist compositions and anti-reflection film materials using such copolymers
JP4792971B2 (ja) 2003-06-26 2011-10-12 大正製薬株式会社 ２−アミノ−ビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸エステル誘導体
JP5485492B2 (ja) * 2004-12-15 2014-05-07 大正製薬株式会社 うつ病の予防・治療薬
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
AU2008297876B2 (en) 2007-09-14 2011-07-07 Addex Pharma S.A. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
BRPI0816767B8 (pt) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2502897B1 (en) 2009-11-18 2014-07-09 Taisho Pharmaceutical Co., Ltd. Method for producing optically active bicyclo [3.1.0]hexane derivative using enzyme
US8642777B2 (en) * 2009-11-19 2014-02-04 Taisho Pharmaceutical Co., Ltd Process for producing 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative and intermediate thereof
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
MX2013005623A (es) 2010-11-18 2013-07-05 Lilly Co Eli Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
TWI520935B (zh) 2010-11-18 2016-02-11 美國禮來大藥廠 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物
US9296710B2 (en) 2011-06-17 2016-03-29 Eli Lilly And Company Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist
WO2013062680A1 (en) * 2011-10-25 2013-05-02 Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders
RU2496495C2 (ru) * 2011-12-05 2013-10-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт нормальной физиологии имени П.К. Анохина РАМН ПРИМЕНЕНИЕ СЕЛЕКТИВНОГО АНТАГОНИСТА ГЛУТАМАТНЫХ РЕЦЕПТОРОВ Ro-256981 ДЛЯ НАПРАВЛЕННОГО ВЛИЯНИЯ НА КОГНИТИВНЫЕ ФУНКЦИИ
HUE034513T2 (en) * 2012-06-01 2018-02-28 Taisho Pharmaceutical Co Ltd Fluorinated amino acid prodrug
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102461134B1 (ko) 2014-01-21 2022-10-28 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
AU2017254266B2 (en) 2016-04-18 2021-03-11 Taisho Pharmaceutical Co., Ltd. Prodrug of amino acid derivative
JP7314494B2 (ja) * 2017-10-17 2023-07-26 大正製薬株式会社 アミノ酸誘導体のプロドラッグを含有する医薬
KR20220062838A (ko) 2020-11-09 2022-05-17 대우조선해양 주식회사 선박의 전가동 러더 및 이를 구비한 선박
JP2024004505A (ja) * 2020-11-26 2024-01-17 大正製薬株式会社 アミノ酸誘導体の製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017950A1 (en) 1995-11-16 1997-05-22 Eli Lilly And Company Shoulder prosthesis
ZA969485B (en) 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
CN1247527C (zh) 1998-08-31 2006-03-29 大正制药株式会社 6－氟双环[3.1.0]己烷衍生物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
CH694053A5 (de) 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
AU5667900A (en) * 1999-06-30 2001-01-22 Prescient Neuropharma Inc. 2-aminoindane analogs
NZ522674A (en) 2000-05-11 2004-10-29 Kenneth Curry Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof
KR20030017562A (ko) 2000-06-28 2003-03-03 다이쇼 세이야꾸 가부시끼가이샤 신규 디카르복실산 유도체
DK1379511T3 (da) * 2001-04-12 2005-11-07 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-on-derivater som mGLuR2-antagonister II

Also Published As

Publication number Publication date
PL371014A1 (en) 2005-06-13
PL208123B1 (pl) 2011-03-31
KR20090031962A (ko) 2009-03-30
CN1281274C (zh) 2006-10-25
ZA200404795B (en) 2005-08-31
MXPA04006322A (es) 2004-10-04
JP4230919B2 (ja) 2009-02-25
RU2004122916A (ru) 2005-03-27
CY1108380T1 (el) 2014-02-12
NO328844B1 (no) 2010-05-25
KR20040068348A (ko) 2004-07-30
RU2315622C2 (ru) 2008-01-27
WO2003061698A1 (fr) 2003-07-31
CN1610557A (zh) 2005-04-27
ZA200502085B (en) 2005-08-31
US20050119345A1 (en) 2005-06-02
BR0215462A (pt) 2004-11-30
NO20042530D0 (no) 2004-06-16
PT1459765E (pt) 2008-10-03
CA2471642C (en) 2011-05-24
US7157594B2 (en) 2007-01-02
EP1459765B1 (en) 2008-08-20
NZ533699A (en) 2006-05-26
CA2471642A1 (en) 2003-07-31
AU2002359923B2 (en) 2007-12-20
DE60228491D1 (en) 2008-10-02
ATE405289T1 (de) 2008-09-15
KR100897970B1 (ko) 2009-05-18
HU228436B1 (en) 2013-03-28
EP1459765A4 (en) 2006-05-31
SI1459765T1 (sl) 2009-02-28
HK1073258A1 (en) 2005-09-30
HUP0402649A2 (hu) 2005-10-28
NO20042530L (no) 2004-09-22
JPWO2003061698A1 (ja) 2005-05-19
ES2311642T3 (es) 2009-02-16
EP1459765A1 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
ATE405289T1 (de) 6-fluorobicyclo 3.1.0 hexan-derivate
EP1553089A4 (en) ANTAGONIST OF MELANINE CONCENTRATING HORMONE RECEPTOR, CONTAINING A BENZIMIDAZOLE DERIVATIVE AS AN ACTIVE SUBSTANCE
DE69328856D1 (de) Hypoglykämische Dihydrochalconderivate
ATE223378T1 (de) Prolineamid-derivate
WO2002010154A3 (en) Substituted heterocyclic amides
HK1076816A1 (da)
AU2003246100A1 (en) Amide derivative
NO20061832L (no) Karboksamidderivat av amidtype
ATE272617T1 (de) Sulfonamid-derivate
DK1043310T3 (da) Biphenylamidinderivater
WO2003035610A1 (fr) Derive de sulfonamide a effet inhibiteur sur les mmp
DE60130766D1 (de) Serotoninwiederaufnahme-inhibitoren
DK0978506T3 (da) 2-phenoxyanilinderivater
ATE283840T1 (de) Chondrogonese promotoren und indolin-2-on derivate
BRPI0511824A (pt) radiossensibilizador
ATE286878T1 (de) 3,4-dihydro-1h-naphthalin-derivate als hoch selektive cyclooxygenase-2-inhibitoren
DE60001205D1 (de) Azolderivative oder deren Salze
ATE319452T1 (de) Arzneimittel gegen essstörungen
ATE289601T1 (de) Benzopyran derivate und diese enthaltende antiallergisches mittel
TR28240A (tr) Amidotiofosfat türevi ve aktif engrediyan olarak bunu iceren insektisid, nematosid ve akarisid.